ELIAS JOSEPH JABBOUR to Histone Deacetylase Inhibitors
This is a "connection" page, showing publications ELIAS JOSEPH JABBOUR has written about Histone Deacetylase Inhibitors.
Connection Strength
0.630
-
Deacetylase inhibitors for the treatment of myelodysplastic syndromes. Leuk Lymphoma. 2015 May; 56(5):1205-12.
Score: 0.378
-
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015 Feb 15; 121(4):556-61.
Score: 0.092
-
Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol. 2012 Jan; 87(1):127-9.
Score: 0.075
-
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023 01; 29(1):115-126.
Score: 0.041
-
Current and future management options for myelodysplastic syndromes. Drugs. 2010 Jul 30; 70(11):1381-94.
Score: 0.017
-
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9.
Score: 0.013
-
Clinical experience with decitabine in North American patients with myelodysplastic syndrome. Ann Hematol. 2005 Dec; 84 Suppl 1:18-24.
Score: 0.012